Loading clinical trials...
Loading clinical trials...
Observational Study of the Impact on Quality-of-life of a Switch From a Virologically Effective Regimen to a Regimen Containing a Non-Nucleoside Reverse Transcriptase Inhibitor (QUALVI) Nevirapine (Viramune®) Clinical Phase IV
Conditions
Interventions
Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTI)
Start Date
June 1, 2004
Primary Completion Date
February 1, 2006
Last Updated
July 16, 2014
NCT06694805
NCT04142047
NCT07428330
NCT07225530
NCT05897099
NCT06665646
Lead Sponsor
Boehringer Ingelheim
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions